Hear 45 Presentations from Top Pharma at Drug Discovery Chemistry in San Diego

Cambridge Healthtech Institute's 15th Annual Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma and biotech. As in the past, speaker participation by industry is once again very strong, with presentations from AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly,F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, NoviraPfizer, Takeda and UCB Pharma. Preview the more than 45 presentations* below:

AbbVie
Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
Andrew Petros, PhD, Senior Principal Research Scientist, Protein & Assay Sciences

Applying Biophysical Tools for Lead Identification, Validation and Optimization – Case Studies and Lessons Learned
Anup Upadhyay, PhD, Senior Scientist III, Drug Discovery Science & Technology

Amgen
High-Throughput Mass Spectrometric Analysis of Covalent Protein-Inhibitor Adducts for the Discovery of KRAS G12C Inhibitors
John McCarter, PhD, Head, Affinity Screening Technologies

ADME Properties of PROTACs and Oral Bioavailability Improvement Strategies
Upendra Dahal, PhD, Senior Scientist, Pharmacokinetics and Drug Metabolism

AstraZeneca
Using cryo-EM to Understand RET Receptor Tyrosine Kinase Activation by Neurturin and GFRα2
Jenny Sandmark, PhD, Associate Principal Scientist, Drug Discovery

Targeting the Kringle Domains of Apolipoprotein(a)
Jenny Sandmark, PhD, Associate Principal Scientist, Drug Discovery

Biogen
Discovery of Brain-Penetrant ASK1 Inhibitors for the Treatment of Neurological Diseases
Felix Gonzalez Lopez de Turiso, PhD, Team Leader, Medicinal Chemistry, Drug Discovery

Machine Learning Models for Optimizing Brain Penetrant Kinase Inhibitors
Istvan J. Enyedy, PhD, Principal Scientist

Discovery and Development of BIIB068: A Selective, Potent, Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK)
Bin Ma, PhD, Senior Scientist, Medicinal Chemistry

Boehringer Ingelheim
Targeting Mutant KRAS by Direct and Indirect Approaches
Michael Gmachl, PhD, Principal Scientist, New Therapeutic Concepts

Bristol-Myers Squibb
A Macrocyclic Inhibitor of PDL1
Paul Scola, PhD, Senior Scientist, Medicinal Chemistry

Celgene
New Activities for Cereblon Modulators
Philip Chamberlain, DPhil, Executive Director, Structural and Chemical Biology

Eli Lilly
Talk Title to be Announced
Sepideh Afshar, PhD, Principal Research Scientist, Department of Protein Engineering

F. Hoffmann-La Roche
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni, PhD, Expert Scientist, Medicinal Chemistry

FIRESIDE CHAT: What Lies Ahead?
Hasane Ratni, PhD, Expert Scientist, Medicinal Chemistry

Genentech, Inc.
Label-Free Biosensing for Meeting the Challenges of Increasingly Diverse Chemical Matter
John Quinn, Biophysical Group, Biochemical and Cellular Pharmacology

Medicinal Chemistry: Where Are We Headed?
Wendy Young, PhD, Senior Vice President, Small Molecule Discovery, Genentech

Constrained Peptides for Drug Discovery
Rami Hannoush, PhD, Principal Scientist, Group Leader, Early Discovery Biochemistry

Identification of Novel Macrocyclic Bactericidal Inhibitors Targeting the Essential Bacterial ABC transporter MsbA
Christian Cunningham, PhD, Scientist, Early Discovery Biochemistry

Regulation of Inflammatory Cell Death Signaling by RIP Kinases
Domagoj Vucic, PhD, Principal Scientist, Early Discovery Biology

Local Metabolism Leads to Better Understanding of Tissue Drug Concentration for New Modalities
Donglu Zhang, PhD, Principal Scientist, Drug Metabolism and Pharmacokinetics

In vitro ADME Challenges in Assessing New Modalities
Zhengyin Yan, PhD, Principal Scientist, Department of Drug Metabolism and Pharmacokinetics

Gilead Sciences, Inc.
Model Informed Human Pharmacokinetics and Dose Prediction: Beyond IVIVE of Compound Enzyme Stability
Yurong Lai, PhD, FAAPS, Senior Director, Drug Metabolism

GlaxoSmithKline
Fragment Synergies to Deliver Multiple Shots at Moving Targets
Chun-Wa Chung, PhD, Director, Structural & Biophysical Sciences

Discovery of STING Agonist with Systemic Anti-Tumor Response
Scott Pesiridis, PhD, Associate Fellow, Scientific Leader, Discovery Biology

DEL-Enabled Discovery of Novel MoA and Structurally Unique IDO1 Inhibitors
Bing Xia, PhD, NCE Encoded Library Technologies, RD Medical Science & Technology

Before and After IDO1 ELT Selection: Protein Construct Assessment and High Throughput Binder Confirmation
Eric Shi, PhD, Investigator, Encoded Library Technologies, NCE Molecular Discovery

Targeting Focal Adhesion Kinase with PROTACs: From Tool to in Vivo
Robert Law, PhD, Investigator, Medicinal Chemistry

Janssen
Application of Large-Scale FEP Simulations for Lead Optimization
Tara Mirzadegan, PhD, Senior Director, US Head of Computational Chemistry

Biophysical Techniques to Identify Aggregating Compounds and Select Hits
Samantha Allen, PhD, Principal Scientist, Discovery Sciences

Merck
Characterization of Novel STING Ligands
Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology

Discovering Novel RNA-Binding Proteins for Small Molecule Drug Discovery
Pramod Pandey, PhD, Principal Scientist

Talk Title to be Announced
Payal Sheth, PhD, Executive Director of Mass Spectrometry & Biophysics

Novartis
Encoded Macrocyclic Peptide Libraries in Drug Discovery
Christoph Dumelin, PhD, Laboratory Head and Project Leader, Chemical Biology & Therapeutics

Leveraging Viral Protein-Protein Interactions to Generate Inhibitors of BK and JC Polyomavirus in Early-Stage Drug Discovery
Charles Warthchow, PhD, Senior Investigator, Global Discovery Chemistry

Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery
Jonas Schaefer, PhD, Laboratory Head, Encoded Library Technologies, Novartis Institutes for Biomedical Research, Chemical Biology & Therapeutics (CBT)

Drugging RNA
Natalie Dales, PhD, Director, Global Discovery Chemistry

Novira
Identification of a New Class of HBV Capsid Assembly Modulator
Scott Kuduk, PhD, Scientific Director, Discovery Chemistry

Pfizer
Determining Affinity from Irreversible Thermal Shifts
Justin Hall, PhD, Principal Scientist, Structural Biology & Biophysics

Target Engagement and Protein Degradation: Lessons Learned and Future Applications
Denise Field, PhD, Senior Scientist, I&I Chemistry and Chemical Biology

CryoEM for Drug Discovery against ‘Immuno’ Important Membrane Proteins
Seungil Han, PhD, Cryo-EM Lab Head, Structural & Molecular Sciences

A Solution Phase Platform to Characterize Chemical Reaction Compatibility with DNA-Encoded Chemical Library Synthesis
Anokha Ratnayake, PhD, Principal Scientist, Design and Synthesis Sciences, DNA Encoded Library Technology (DELT) Group

Methods for Estimating Affinity from DEL Primary Selection Data
Justin Hall, PhD, Principal Scientist, Structural Biology & Biophysics

RNA Splicing Modulation… Application to CD33
Tom Chappie, Associate Research Fellow

In vitro and in silico Tools to Facilitate the Assessment of Transporter-Mediated Drug Interactions
Cen Guo, PhD, Manager, Clinical Pharmacology

Takeda
Understanding the Applicability and Limitations of in silico and in vitro Safety Models towards the Design and Selection of the Safest Drug Candidates
Takafumi Takai, PhD, Senior Scientist, Discovery Toxicology, Drug Safety Research & Evaluation

UCB Pharma
Applied Machine Learning in Compound Mechanism Deconvolution
Yuan Wang, PhD, Senior Principal Scientist, Head of TPD Data Science, UCB Pharma

Computational Exploration of Novel Drug Targets, Modalities, and Design
Yuan Wang, PhD, Senior Principal Scientist, Head of TPD Data Science, UCB Pharma


* As of 1/08/20 – Please see individual agenda pages for most up-to-date list of speakers